Mon, Dec 22, 2014
A A A
Welcome Guest
Free Trial RSS
Get FREE trial access to our award winning publications
New Managers July 2012

Focus - What emerging managers need to know: a review

What emerging managers need to know: a review

IIR and IBC's recent Hedge Fund Startup Forum in London, which Opalesque attended, gave a complete roundup of what emerging hedge fund managers should do and expect. It touched on asset raising, recent trends, the role of the prime broker and the administrator, tax issues, seeding, regulatory compliance, and what investors look for. Here are some of the key points that emerged.

Want to raise assets from institutions?

Ian Morley The basic advice for start-up managers is, don't waste your time talking to institutions," said Ian Morley in the conference's opening remarks. "Raise your initial seed money from friends, family, platforms and those of an unsound mind." Morley was the founding Chairman of AIMA, the hedge fund organisation, and headed various funds of funds. He is Chairman of Allenbridge HedgeInfo, a hedge fund rating and consulting company, and of Wentworth Hall Consultancy.

However, for those who do decide to approach institutions, Morley suggested having the following boxes ticked:

  • A proper business plan
  • Could you run for three years on your initial capital?
  • Will your operational infrastructure meet institutional standards?
  • Do you have a unique selling point in your pitch?

To get over the first hurdles, you need to see if there is a consultant you must deal with first, and if the pension scheme you want to connect with is private or public. The latter ......................

To view our full article please login

This article was published in Opalesque's New Managers a top-down monthly analysis, news and research publication on the global emerging manager space.
New Managers
New Managers
New Managers

Today's Exclusives Today's Other Voices More Exclusives
Previous Opalesque Exclusives                                  
More Other Voices
Previous Other Voices                                               
Access Alternative Market Briefing


  • Top Forwarded
  • Top Tracked
  • Top Searched
  1. Investing - Big hedge funds win again on PetSmart, Riverbed, RBS sells real estate loans to hedge fund Cerberus, Talisman energy speculation: Which hedge funds could benefit?[more]

    Big hedge funds win again on PetSmart, Riverbed From CNBC.com: Another week, another set of wins for activist investors. On Sunday, pet supply retailer PetSmart agreed to the largest leveraged buyout of the year at $8.7 billion. Hedge fund firm JANA Partners had been pushing for a sale a

  2. Outlook - Hedge fund manager who remembers 1998 rout says prepare for pain, Bond guru Bill Gross predicts U.S. economic growth to dip to 2%[more]

    Hedge fund manager who remembers 1998 rout says prepare for pain From Bloomberg.com: Stephen Jen landed in Hong Kong in early January 1997 as Morgan Stanley’s newly minted exchange-rate strategist for Asia. He was soon working around the clock when investors began targeting the region’s

  3. Investing - Hedge funds get boost from healthcare in 2014, Paulson & Co takes stake in Salix on heels of inventory issues[more]

    Hedge funds get boost from healthcare in 2014 From Valuewalk.com: The healthcare sector started the year on a turbulent note, as stocks of many major biotechnology companies were battered. However, most of the players in this sector have bounced back. The BarclayHedge Healthcare & Biotec

  4. North America - Why Steve Cohen, Connecticut hedge fund billionaire, gives so much in New York[more]

    From Insidephilantrophy.com: Billionaire Steve Cohen was born in Great Neck, New York before attending Wharton, working on Wall Street and then founding SAC Capital Advisors in Connecticut. Though his company (Point72) and foundation are based in Connecticut, Cohen and Alexandra are deeply connected

  5. Investing - Soros buys a highly speculative biotech in the third quarter[more]

    From Fool.com: …The Soros Fund bought 25,000 shares of the struggling small-cap biopharma Aegerion Pharmaceuticals in the third quarter. For those of you who haven't heard of this name, suffice to say that this was a surprising buy in light of the company's recent problems and poor outlook going for